[Immune and enzyme disorders in patients with acute pancreatitis].
Briskin. B S BS; Iarovaia. G A GA; Savchenko. Z I ZI; Rybakov. G S GS; Khalidov. O Kh OKh; Mkhitarova. L A LA; Suplotova. A A AA
Key Findings
- Persistent imbalance of regulatory T‑lymphocytes with a dominance of suppression
- Reduced levels of all immunoglobulins and altered neutrophil function (high absorption, low digestive capacity)
- Higher leukocytic elastase activity and lower alpha‑1‑proteinase inhibitor levels predict severe disease and poorer prognosis
Practical Outcomes
- For most biohackers, the findings are not directly actionable because they involve clinical biomarkers and treatments used in hospitals. It does highlight that monitoring leukocytic elastase and alpha‑1‑proteinase inhibitor could signal severe pancreatitis, and that immune‑modulating agents (immunocorrectors) might be worth exploring, but no specific dosing or protocol for thymalin is provided.
Summary
The study looked at 85 people with acute pancreatitis and found that their immune system was out of balance, with fewer helpful immune cells and antibodies, and weird neutrophil activity. These immune problems were linked to worse outcomes, and the researchers say measuring certain enzymes in the blood can help track disease severity and treatment success, suggesting that adding immune‑modulating drugs might improve results.
Abstract
Analysis of immune and enzyme disorders in 85 patients with acute pancreatitis shows that persistent imbalance of immunoregulatory T-lymphocytes with suppression predominance; reduction of all immunoglobulines number, imbalance in phagocytic immunity with height of absorbing activity of neutropils and stimultaneous decrease of their digestive capacity are prognostically unfavourable for high risk of pyonecrotic complications and lethal outcome. It is necessary to include immunocorrectors in combined therapy. Direct assessment of leukocytic elastase activity and alpha-IP level in blood plasma permits to evaluate spreading of inflammatory process and it severity, efficacy and prognosis of treatment.
Study Information
pubmed
2001